Compounds > n-solanesyl-n,n'-bis(3,4-dimethoxybenzyl)ethylenediamine

Page last updated: 2024-08-02 00:53:20

n-solanesyl-n,n'-bis(3,4-dimethoxybenzyl)ethylenediamine

Description

N-solanesyl-N,N'-bis(3,4-dimethoxybenzyl)ethylenediamine: structure given in first source [MeSH]

Cross-References

ID Source	ID
PubMed CID	6447858
CHEMBL ID	1188103
MeSH ID	M0139911

Synonyms (5)

Synonym
n-solanesyl-n,n'-bis(3,4-dimethoxybenzyl)ethylenediamine
1,2-ethanediamine, n,n'-bis((3,4-dimethoxyphenyl)methyl)-n-(3,7,11,15,19,23,27,31,35-nonamethyl-2,6,10,14,18,22,26,30,34-hexatriacontanonaenyl)-
n,n'-bis[(3,4-dimethoxyphenyl)methyl]-n'-[(2e,6e,10e,14e,18e,22e,26e,30e)-3,7,11,15,19,23,27,31,35-nonamethylhexatriaconta-2,6,10,14,18,22,26,30,34-nonaenyl]ethane-1,2-diamine
CHEMBL1188103
104845-40-1

Research

Studies (10)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (40.00)	18.7374
1990's	5 (50.00)	18.2507
2000's	1 (10.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	1 (10.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (90.00%)	84.16%

Substance	Studies	Classes	Roles	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
verapamil	2	aromatic ether; nitrile; polyether; tertiary amino compound		1986	1991	35.5	medium	0	1	1	0	0	0
fluorouracil	1	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic	1990	1990	34.0	low	0	0	1	0	0	0
cytarabine	2	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent	1990	2002	28.0	medium	0	0	1	1	0	0
cepharanthine	1	bisbenzylisoquinoline alkaloid; isoquinolines		1992	1992	32.0	low	0	0	1	0	0	0
daunorubicin	1	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite	1991	1991	33.0	low	0	0	1	0	0	0
azides	1	pseudohalide anion	mitochondrial respiratory-chain inhibitor	1991	1991	33.0	low	0	0	1	0	0	0
dihydropyridines	1			1991	1991	33.0	low	0	0	1	0	0	0
dactinomycin	1	actinomycin	mutagen	1990	1990	34.0	low	0	0	1	0	0	0
azidopine	1	benzamides		1991	1991	33.0	low	0	0	1	0	0	0
zinostatin	1			1990	1990	34.0	low	0	0	1	0	0	0
peplomycin	1	glycopeptide		1990	1990	34.0	low	0	0	1	0	0	0
epidermal growth factor	1			1987	1987	37.0	low	0	1	0	0	0	0

Condition	Indicated	Studies	First Year	Last Year	Average Age	Relationship Strength	Trials	pre-1990	1990's	2000's	2010's	post-2020
Adenocarcinoma Of Kidney	0	1	1992	1992	32.0	low	0	0	1	0	0	0
Cancer of Kidney	0	1	1992	1992	32.0	low	0	0	1	0	0	0
Cancer of Liver	0	1	1990	1990	34.0	low	0	0	1	0	0	0
Cancer of Mouth	0	1	1995	1995	29.0	low	0	0	1	0	0	0
Carcinoma, Epidermoid	0	3	1986	1995	34.7	medium	0	2	1	0	0	0
Carcinoma, Hepatocellular	0	1	1990	1990	34.0	low	0	0	1	0	0	0
Carcinoma, Renal Cell	0	1	1992	1992	32.0	low	0	0	1	0	0	0
Carcinoma, Squamous Cell	0	3	1986	1995	34.7	medium	0	2	1	0	0	0
Experimental Leukemia	0	1	1986	1986	38.0	low	0	1	0	0	0	0
Hepatocellular Carcinoma	0	1	1990	1990	34.0	low	0	0	1	0	0	0
Kidney Neoplasms	0	1	1992	1992	32.0	low	0	0	1	0	0	0
Leukemia P388	0	1	1986	1986	38.0	low	0	1	0	0	0	0
Liver Neoplasms	0	1	1990	1990	34.0	low	0	0	1	0	0	0
Mouth Neoplasms	0	1	1995	1995	29.0	low	0	0	1	0	0	0

Safety/Toxicity (1)

Article	Year
Enhancement by a synthetic isoprenoid of the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin. Biochemical pharmacology, , Mar-15, Volume: 36, Issue:6	1987